Christoph D. Brandenberger Quoted in, “2024 Dx M&A Market Remains Quiet as Industry Looks for Improvement in 2025,” 360Dx

BGL Managing Director Christoph D. Brandenberger, who leads the firm’s Diagnostics, Research Tools & Medical Devices investment banking team, is quoted in a 360Dx article entitled, “2024 Dx M&A Market Remains Quiet as Industry Looks for Improvement in 2025.”

In the article, Christoph examines key investor themes and provides his outlook on the diagnostics landscape for 2025.

For all of Christoph’s insights on M&A trends in the diagnostics market, including his predictions for 2025, read the complete article on the 360Dx website (subscription required).